BPC-157 and TB-500 Dosage Guide: The Wolverine Stack Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Written by Sam Brooks · Published / Reviewed July 24, 2026

Educational information only. This guide is not medical advice and is not a set of self-administration instructions. BPC-157 and TB-500 are not FDA-approved drugs. Any peptide protocol must be prescribed, dosed, and supervised by a licensed physician who knows your medical history. Do not attempt to source, reconstitute, or inject these peptides on your own.

Quick Wolverine Stack Dosing Summary

The “Wolverine Stack” pairs BPC-157 and TB-500 to support soft-tissue recovery from two complementary angles. In the most commonly referenced physician-directed research protocols, BPC-157 is dosed at roughly 250–500 mcg per day by subcutaneous injection, while TB-500 uses a two-phase schedule: a loading dose of about 2–2.5 mg twice weekly (≈4–5 mg/week) for 4–6 weeks, followed by a maintenance dose of about 2–2.5 mg once weekly. Typical combined cycles run 4–8 weeks. These figures come from animal studies and clinical practice, not from large human efficacy trials.

At-a-Glance Combined Protocol

Read the full guide below for the reasoning behind stacking these two peptides, combined reconstitution and syringe math, whether they can be drawn into the same syringe, cycle design, and an honest look at the evidence and 2026 regulatory status. Schedule a Peptide Therapy Consultation to review whether a supervised protocol is appropriate for you.

What Is the Wolverine Stack?

The Wolverine Stack is a nickname — a nod to the comic-book character’s rapid healing — for the combined use of two research peptides, BPC-157 and TB-500, aimed at supporting recovery from tendon, ligament, muscle, and connective-tissue injuries. Neither peptide is a drug approved by the U.S. Food and Drug Administration (FDA), and the “stack” itself has never been studied as a fixed combination in a controlled human trial. What follows is an educational summary of how each peptide is understood to work and how clinicians who use them under supervision typically frame dosing.

BPC-157 in Brief

BPC-157 (Body Protection Compound-157) is a synthetic, stable pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a protein found in human gastric juice. In animal models it has been associated with accelerated healing of tendon, muscle, ligament, and gastrointestinal tissue, largely through effects on new blood-vessel formation (angiogenesis), fibroblast migration, and growth-factor signaling. It is thought to act primarily as a local tissue-repair agent and to have a notable protective effect on the gut lining.

TB-500 in Brief

TB-500 is a synthetic peptide related to thymosin beta-4 (Tβ4), a naturally occurring protein present in nearly all human cells and in high concentration in wound fluid and platelets. Tβ4 is the body’s main G-actin–sequestering peptide, meaning it manages the pool of actin that cells use to change shape and migrate. Through this actin regulation it promotes cell migration, angiogenesis, and tissue remodeling across the whole body. Because of that systemic reach, TB-500 is generally described as the “global” partner in the stack.

Why the Two Are Combined

The rationale for stacking is that the two peptides are thought to work through complementary, non-overlapping mechanisms. BPC-157 is positioned as the local specialist — concentrated repair activity, angiogenesis at the injury site, and gut protection — while TB-500 is positioned as the systemic partner that improves cell migration and blood-vessel formation body-wide. In theory, one lays down the local repair environment while the other recruits the cells and vasculature needed to rebuild tissue. It is important to be clear that this complementary model is a mechanistic hypothesis extrapolated from separate animal and cell studies, not a proven clinical synergy demonstrated in humans.

Where the “Wolverine” Name Comes From

The term is fitness-community slang rather than a medical designation. It borrows from the fictional character known for near-instant recovery, and it became attached to the BPC-157 + TB-500 pairing because both peptides are marketed around the idea of faster tissue healing. No clinician coined the phrase, and no product with that name is FDA-cleared. Understanding that the label is marketing, not medicine, is the right starting frame: it sets expectations honestly and underscores that a memorable nickname is not evidence of efficacy.

How BPC-157 and TB-500 Work: Mechanisms in Depth

Understanding the proposed biology helps explain both the appeal of the stack and the limits of the evidence. The mechanisms below are drawn largely from animal and cell-culture research; extrapolating them to human injury recovery requires caution.

The Angiogenesis Pathway (VEGF)

Both peptides are described as pro-angiogenic — they are associated with the formation of new blood vessels, which is a rate-limiting step in healing poorly-vascularized tissue like tendon and ligament. BPC-157 has been linked in rodent studies to upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and to the nitric-oxide (NO) system, both of which support new vessel growth and blood-flow regulation in injured tissue. TB-500, through thymosin beta-4 biology, is likewise described as promoting endothelial cell migration and tubule formation. The shared angiogenic theme is part of why they are paired — and also part of why an active-cancer history is treated as a contraindication, since tumors also depend on angiogenesis.

BPC-157 and the Gut and Connective-Tissue Axis

BPC-157’s origin as a fragment of a protein found in gastric juice is reflected in one of its most-discussed properties: apparent protection of the gastrointestinal lining in animal models, including protection against NSAID-induced damage. Beyond the gut, preclinical work associates it with fibroblast recruitment, collagen organization, and up-regulation of the growth-hormone receptor in tendon fibroblasts — a plausible route to stronger tendon-to-bone healing in the models studied. These are the findings that position BPC-157 as the “local repair and gut” member of the stack.

TB-500 and Actin Sequestration

Thymosin beta-4 is the body’s principal G-actin–sequestering peptide. By binding monomeric actin, it maintains a reservoir the cell can rapidly polymerize when it needs to change shape and crawl toward a wound. Because keratinocytes, fibroblasts, and endothelial cells all migrate into injured tissue to rebuild it, this actin management is thought to be the engine behind TB-500’s systemic pro-healing and pro-migration reputation. A short seven–amino-acid actin-binding motif has been identified as essential to its angiogenic activity, tying the actin and blood-vessel effects together.

Why the Mechanisms Are Framed as Complementary

Put simply: TB-500 is proposed to mobilize and migrate the cells and build the vasculature across the whole system, while BPC-157 is proposed to concentrate repair signaling, protect tissue, and support angiogenesis right where the injury sits. That division of labor — systemic recruitment plus local repair — is the entire theoretical basis of the stack. It is a coherent story, but it remains a story assembled from separate experiments rather than one tested head-to-head in people.

BPC-157 and TB-500 Dosing Protocols Based on Research

There is no established, FDA-sanctioned dose for either peptide, because neither is an approved drug. The ranges below reflect what appears in the preclinical literature and in clinician-directed practice. They are provided for education, and any actual protocol must be individualized by a prescribing physician.

Standard BPC-157 Dosing Ranges

BPC-157 is most often described in the 200–500 mcg per day range, given subcutaneously. Many practitioners split the daily amount into two doses (for example, 250 mcg in the morning and 250 mcg in the evening) on the theory that the peptide has a short half-life and more frequent dosing keeps tissue levels steadier. When a specific injury is being targeted, BPC-157 is often injected subcutaneously in the region nearest the injury. A frequent point of confusion is that BPC-157 is dosed in micrograms (mcg) while TB-500 is dosed in milligrams (mg) — a 1,000-fold difference in scale. Mixing up the units is one of the most dangerous errors possible with this stack, which is another reason preparation and dosing belong with a clinician rather than being improvised at home. There is no established maximum “safe” dose because there are no dose-ranging human trials; the ranges here simply reflect what appears in the literature and practice, not a validated ceiling.

Standard TB-500 Dosing Ranges

TB-500 dosing is usually structured in two phases. A loading phase uses a higher, more frequent dose — commonly about 2–2.5 mg twice weekly (roughly 4–5 mg total per week) — for 4–6 weeks to build tissue levels. This is followed by a maintenance phase at a lower frequency — commonly about 2–2.5 mg once weekly, or a reduced dose every other week — to sustain the effect. Because TB-500 is understood to act systemically, the injection site is generally considered unimportant, and the abdomen is a common choice for comfort.

Combined Wolverine Stack Dosing Tiers

The table below organizes the stack into conservative, standard, and aggressive tiers. Higher tiers are not “better” — they simply reflect the wider ranges that appear in the literature, and they carry more uncertainty. A physician decides where an individual should sit.

Clinical Trial Data and Evidence Quality

Honesty about evidence is essential here. The great majority of BPC-157 research is preclinical — rodent and in-vitro studies, most from a single research group in Croatia. There are no completed large-scale human efficacy trials for BPC-157 in tendon or muscle injury. The rodent tendon work is genuinely interesting — for example, studies have documented accelerated tendon-fibroblast outgrowth, increased fibroblast migration, improved cell survival under oxidative stress, and up-regulation of the growth-hormone receptor in tendon fibroblasts — but rodent healing biology does not automatically translate to humans, and dose, delivery, and injury models in those studies differ from real-world use. Treating strong animal findings as if they were proven human outcomes is the central error to avoid when reading about this stack.

For TB-500, the relevant human data comes from studies of the full parent molecule, thymosin beta-4, delivered as a topical or intravenous formulation for chronic wounds, not as the injectable “TB-500” fragment used in fitness settings. Randomized human trials of thymosin beta-4 gel (developed as RGN-137 by RegeneRx under a license from the National Institutes of Health) showed acceleration of dermal healing in pressure and venous-stasis ulcers, with the therapy generally well tolerated. That is meaningful, but it is not the same molecule, route, or indication as injectable TB-500 for a torn tendon. The specific TB-500 fragment sold for research has no human efficacy trials of its own, and at least one in-vitro evaluation cited by the FDA found it did not induce wound healing in fibroblast cultures. In short: promising mechanisms, thin and indirect human evidence, and no controlled trial of the two combined.

How to Reconstitute BPC-157 and TB-500

Both peptides are supplied as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before use. In a supervised setting, a pharmacist or clinician prepares the vials. The steps below explain the process so you understand what is involved — they are not an instruction to do this yourself.

Step-by-Step Reconstitution

1. Bring supplies to room temperature and sanitize the work surface. You will need the peptide vial, bacteriostatic water (not sterile or tap water — the benzyl alcohol in bacteriostatic water suppresses microbial growth for multi-dose use), alcohol swabs, and an appropriate syringe.
2. Swab both rubber stoppers — the peptide vial and the bacteriostatic water vial — with alcohol and let them dry.
3. Draw the chosen volume of bacteriostatic water into a reconstitution syringe.
4. Inject the water slowly down the inside wall of the peptide vial, aiming the stream at the glass rather than directly onto the powder to reduce foaming and protect the peptide.
5. Do not shake. Gently swirl or roll the vial until the powder fully dissolves into a clear solution. Shaking can damage the peptide.
6. Label with the peptide name, concentration, and reconstitution date. Store both reconstituted vials refrigerated at 2–8°C and use within about 3–4 weeks. Never freeze a reconstituted solution.

Reconstitution and Concentration Reference

These are worked examples for a standard 1 mL U-100 insulin syringe, where 100 units = 1 mL and each unit = 0.01 mL. Choosing a concentration that lands your dose at a clean number of units reduces measurement error.

Dosing Calculation Examples with Syringe Math

Working the math through for the standard tier:

• BPC-157, 250 mcg dose from a 2 mg/mL vial (20 mcg/unit): 250 ÷ 20 = 12.5 units (0.125 mL). A 500 mcg dose = 25 units.
• BPC-157, 250 mcg dose from a 1 mg/mL vial (10 mcg/unit): 250 ÷ 10 = 25 units (0.25 mL). The more dilute mix gives larger, easier-to-read unit numbers.
• TB-500, 2.5 mg dose from a 5 mg/mL vial (50 mcg/unit): 2,500 ÷ 50 = 50 units (0.5 mL). From a 2.5 mg/mL vial (25 mcg/unit): 2,500 ÷ 25 = 100 units (1.0 mL — a full syringe, so a more concentrated mix is often preferred).

Storage and Handling After Reconstitution

Handling protects both potency and safety. Before reconstitution, the lyophilized powder is generally stored cold and kept away from light. After reconstitution, both peptides are refrigerated at 2–8°C and are typically used within about 3–4 weeks, since bacteriostatic water’s preservative only limits — not eliminates — microbial risk over time. Reconstituted solution should never be frozen, left at room temperature for extended periods, or exposed to heat or direct sunlight, all of which can degrade the peptide. Each vial should be clearly labeled with contents, concentration, and reconstitution date so doses stay accurate and expired vials are discarded rather than used. If a solution becomes cloudy, discolored, or contains particles, it should be discarded.

Can You Draw BPC-157 and TB-500 Into the Same Syringe?

This is one of the most common questions about the stack. Two considerations apply. First, the two peptides are dosed on completely different schedules — BPC-157 daily, TB-500 only once or twice weekly — so on most days there is nothing to combine. On the days the schedules coincide, some clinicians will allow both to be drawn into one syringe for a single injection, since both are typically reconstituted in compatible bacteriostatic water. Others prefer separate injections to keep each dose precise, to allow BPC-157 to be placed near an injury while TB-500 goes in the abdomen, and to avoid any mixing that could complicate dosing accuracy. There is no rigorous compatibility study establishing that co-mixing is fully equivalent. The default, safest practice is to keep them in separate syringes unless a supervising provider specifically directs otherwise.

Wolverine Stack Administration Guide

Both peptides in this stack are given by subcutaneous injection — into the fatty layer just beneath the skin — using a small insulin syringe. The technique is the same for each; the site strategy differs.

Injection Site Selection

For BPC-157, when targeting a specific injury, the subcutaneous injection is often placed in the region closest to the affected tendon or muscle, on the reasoning that local delivery may concentrate its repair effects nearby. For general or gut-related use, the abdomen is standard. For TB-500, because it is understood to distribute systemically, site choice is a matter of comfort — the abdomen (at least two inches from the navel) and the outer thigh are common. Rotate sites to avoid irritation or lumps, and never inject into inflamed, bruised, or broken skin.

Subcutaneous Injection Technique

1. Wash your hands and swab the chosen site with alcohol; let it dry.
2. Draw the prescribed number of units, tapping out air bubbles.
3. Pinch a fold of skin to lift the subcutaneous fat away from muscle.
4. Insert the short insulin needle at a 45–90° angle depending on body fat.
5. Depress the plunger slowly and steadily.
6. Withdraw, apply light pressure with a clean swab, and dispose of the needle in a sharps container.

Injection technique should be taught in person by a clinician. Written steps are for understanding only.

Optimal Timing for the Wolverine Stack

Because BPC-157 has a short half-life, splitting it into a morning and evening dose is a common approach when the daily target is 500 mcg, keeping levels more consistent through the day. Some protocols place a BPC-157 dose close to physical therapy or rehab work on the theory of supporting the healing window, though this is not established by trial data. TB-500’s loading doses are simply spaced across the week (for example, one dose early in the week and one mid-to-late week) rather than tied to time of day, reflecting its longer functional duration. Consistency — same times, same days each week — matters more than the exact clock time.

Food timing is not thought to be critical for subcutaneous dosing of either peptide, so injections can generally be given with or without meals. Some users prefer BPC-157 on an empty stomach out of habit, but there is no strong evidence that this changes subcutaneous absorption. The more practical consideration is building a routine that is easy to keep: a fixed daily slot for BPC-157 and two anchored days each week for TB-500 loading make missed doses less likely, which matters more for a healing protocol than any theoretical timing optimization. If a dose is missed, the usual guidance is to resume the normal schedule rather than double up — but even that decision belongs with the supervising provider, who can tailor it to the individual plan.

Wolverine Stack Cycle Length and Protocol Duration

A combined cycle is most often described as 4–8 weeks, with some longer protocols running 8–12 weeks for stubborn injuries. Within that window, TB-500 typically front-loads (the 4–6 week loading phase) and then steps down to maintenance, while BPC-157 is run daily throughout. Many practitioners then schedule an off period — commonly at least 4 weeks, sometimes matching the on-cycle length — before considering another round, both to reassess whether continued use is warranted and to avoid indefinite dosing of compounds without long-term human safety data. The right duration depends on the injury, the response, and clinical judgment, not on a fixed formula.

Sample Combined Cycle Timeline

Wolverine Stack Safety Profile and Potential Side Effects

Because there are no long-term controlled human safety studies for either peptide — and none for the combination — the safety picture is incomplete by definition. What is reported comes from short animal studies and anecdotal clinical experience. The absence of documented harm is not the same as proven safety.

Commonly Reported Side Effects

• Injection-site reactions: redness, mild pain, swelling, itching, or small lumps.
• Fatigue or lethargy, most often mentioned with TB-500 loading doses.
• Transient lightheadedness, nausea, or headache.
• Flushing or a sensation of warmth after injection.

Contraindications and Serious Concerns

Both peptides promote angiogenesis (new blood-vessel growth) and cell migration. That is the point in wound repair, but it raises a theoretical concern that the same activity could feed the growth or spread of an existing tumor. Because cell migration and new vasculature are also hallmarks of how cancers grow and metastasize, the very mechanisms that make these peptides appealing for healing are the ones that make them worrisome in the presence of malignancy. For that reason, an active or recent history of cancer is treated as a contraindication until far more is known, and any personal or strong family history of cancer should be disclosed and weighed during screening. These peptides should also be avoided in pregnancy and breastfeeding, given the complete absence of safety data in those groups, and are not appropriate for minors. Anyone with significant cardiovascular, kidney, or liver disease, an autoimmune condition, or a history of malignancy should not use them outside of — and arguably not even within — a carefully supervised clinical decision. The honest summary is that the long-term safety of either peptide in humans, and of the two together, is simply not established.

Drug Interactions and Athlete Warning

Formal drug-interaction studies do not exist for either peptide. Patients on anticoagulants, immunosuppressants, or other chronic medications must have any peptide use reviewed by their physician. Separately, both BPC-157 and TB-500 are prohibited in sport at all times under the World Anti-Doping Agency (WADA) Prohibited List — TB-500 as a prohibited peptide/growth factor, and BPC-157 explicitly named among prohibited substances. Any competitive or drug-tested athlete who uses this stack risks a doping violation.

Combining the Wolverine Stack With Other Peptides and Therapies

Beyond each other, BPC-157 and TB-500 are sometimes discussed alongside other recovery- or growth-oriented peptides. The comparison matrix below summarizes how the two stack members and a few frequently mentioned neighbors are positioned. This is educational context, not an endorsement of layering multiple non-approved compounds — each addition compounds the uncertainty and the risk. As a general principle, the more agents added to a regimen, the harder it becomes to attribute any benefit or any side effect to a specific cause, and the thinner the safety data behind the overall combination becomes. Simpler is usually safer, and any decision to combine peptides should be made by a clinician who can weigh the interactions and the goals rather than assembled from stacking guides online.

For deeper single-peptide detail, see the BHRC BPC-157 Dosage Guide and the TB-500 Dosage Guide. To discuss whether any of these belong in a supervised plan, schedule a peptide therapy consultation.

BPC-157 vs TB-500: How They Differ

Patients often ask which peptide to choose if not both. The distinction is scope. BPC-157 is the local, fast-acting repair peptide — dosed daily, often placed near the injury, and uniquely associated with gut and gastrointestinal protection. TB-500 is the systemic, slower-cadence peptide — dosed a couple of times a week, working body-wide through actin regulation to support cell migration and blood-vessel formation. They are stacked precisely because they differ: the theory is that BPC-157 concentrates repair locally while TB-500 supplies the systemic cellular machinery. Choosing one over the other, or using both, is a clinical decision based on the injury and the individual.

Who Should Consider the Wolverine Stack?

In a physician-supervised setting, interest in this stack usually comes from adults dealing with slow-healing soft-tissue injuries — chronic tendinopathy, ligament strains, or muscle injuries that have not responded to conventional rehab. It is not appropriate for anyone with an active or recent cancer history, anyone who is pregnant or breastfeeding, minors, or competitive athletes subject to drug testing. It is also not a substitute for the foundations of recovery: physical therapy, load management, sleep, protein-adequate nutrition, and treating the underlying cause of the injury. A candidate is best defined not by a checklist a person applies to themselves, but by a clinician’s assessment during a full evaluation.

Better-Established Alternatives to Consider First

Because the human evidence for this stack is limited, a thorough evaluation usually looks first at interventions with stronger support: structured physical therapy and progressive loading (the mainstay of tendinopathy care), appropriate rest and activity modification, and, where indicated, treatments a physician can offer with clearer evidence. Peptides, if considered at all, sit as an adjunct within that larger plan rather than as a first-line or stand-alone fix. Framing them this way keeps expectations realistic and keeps the focus on what is most likely to actually help the injury heal.

Questions to Bring to a Consultation

Patients get the most from an evaluation when they arrive ready to discuss the specific injury and its history, what treatments have already been tried, their full medical and medication history (including any cancer history), their goals and timeline, and their questions about evidence, risks, and cost. That information lets a clinician give a genuine recommendation — which may be that a supervised peptide protocol is reasonable to try, or that it is not the right step and something better-supported should come first.

Monitoring Progress and Adjusting Protocols

Supervised use includes follow-up. That typically means tracking the injury objectively — range of motion, pain scores, functional milestones — rather than relying on how a dose “feels.” A sensible framework starts with a baseline evaluation before any peptide is used: a full history, screening for the contraindications above, and appropriate baseline labs. During the cycle, the provider monitors both the target injury and general well-being, and reviews any side effects. Because these peptides affect angiogenesis, a responsible protocol also includes attention to any new or unusual symptoms, with prompt discontinuation and evaluation if anything concerning appears — for example, unexplained lumps or masses, persistent or worsening pain, or systemic symptoms such as unexplained weight loss. Doses are adjusted, tapered, or stopped based on response and tolerance, and cycles are kept finite rather than open-ended. If the injury is not responding to a reasonable trial, the correct next step is to revisit the diagnosis and treatment plan — including imaging or specialist referral — not to keep escalating peptide doses. Bloodwork and clinical review at sensible intervals, and a clear plan for when to stop, are part of doing this responsibly.

Are BPC-157 and TB-500 FDA-Approved? Legal & Regulatory Status (2026)

As of July 24, 2026: neither BPC-157 nor TB-500 is approved by the FDA for any use. Both are handled as research compounds, and both have moved through a period of intense regulatory scrutiny.

• Category 2 removal (April 2026): In mid-April 2026, the FDA removed both BPC-157 and TB-500 (including its acetate and free-base forms) from the Section 503A “Category 2” list — the category that had effectively blocked compounding. Removal from Category 2 is not approval; it simply moved them forward to be considered by an advisory committee.
• PCAC review (July 23–24, 2026): The FDA’s Pharmacy Compounding Advisory Committee met on July 23–24, 2026 to consider whether these peptides should be added to the 503A Bulks List that compounding pharmacies may use. Reporting from that meeting indicates the FDA took an unfavorable position — for TB-500, proposing it not be added, citing an absence of human effectiveness data. BPC-157 was likewise reviewed under a skeptical FDA stance.
• Bottom line: Coming off Category 2, being reviewed for 503A, and receiving FDA drug approval are three different things. At the date of this writing these remain non-approved compounds whose compounding status is unsettled and subject to change. Verify the current status before relying on any of this.

BHRC does not sell raw or research peptides and does not position any non-approved peptide as an approved medicine. Where a supervised protocol is clinically appropriate, it is provided under physician direction. Both peptides are also prohibited in sport by WADA at all times.

What Results to Expect and Realistic Timelines

Expectation-setting is part of responsible education. Anecdotal reports and animal data suggest soft-tissue recovery support rather than a dramatic overnight cure, and outcomes vary widely by injury type, severity, age, and overall health.

Typical Reported Timeline

In practice, people using the stack under supervision often describe changes over weeks, not days. Any perceived reduction in discomfort or improvement in function is usually gradual across a 4–8 week cycle, aligning with TB-500’s loading-then-maintenance structure and BPC-157’s daily use. Because there is no placebo-controlled human trial of the combination, it is impossible to separate genuine peptide effect from the natural course of healing, concurrent physical therapy, and the placebo response — a limitation worth stating plainly.

What the Stack Is Not

The stack is not a replacement for diagnosis and definitive treatment. A structural tear, a fracture, or an injury requiring surgery will not be resolved by peptides, and using them in place of appropriate care can delay necessary treatment. It is also not a performance-enhancing shortcut for healthy athletes — beyond the WADA prohibition, there is no good evidence it improves an uninjured person’s tissue.

Measuring Response Objectively

Rather than judging by feel alone, a supervised plan tracks concrete markers: pain scores, range of motion, load tolerance, and return-to-activity milestones. If objective function is not improving over a reasonable window, that is a signal to reassess the diagnosis and the plan rather than to simply escalate the dose.

Common Wolverine Stack Mistakes to Avoid

Most problems people describe with peptides trace back to process errors rather than the molecules themselves. These are educational cautions, and they reinforce why supervision matters.

Self-Sourcing and Self-Dosing

The single biggest mistake is obtaining peptides from unregulated “research” vendors and dosing without a clinician. Purity, sterility, and actual peptide content cannot be verified from a label, and self-directed dosing removes the medical screening that would catch a contraindication like an undiagnosed malignancy risk. BHRC’s position is that these compounds belong only in a physician-directed context, if at all.

Skipping the Diagnosis

Reaching for a healing stack before the injury has been properly diagnosed can mask or delay treatment of a problem that needs imaging, immobilization, or surgery. Peptides should never be the first move on an unevaluated injury.

Chasing Higher Doses

More is not better. Escalating past the referenced ranges in hopes of faster results increases cost and uncertainty without any evidence of added benefit, and it moves further from the doses that appear in the literature. Dose changes should be a clinical decision.

Ignoring Cycling and Reassessment

Running the stack indefinitely, with no off periods and no reassessment, is inconsistent with responsible use of compounds that lack long-term human safety data. Finite cycles with planned breaks and follow-up are the safer pattern.

Sourcing, Purity, and Cost Considerations

Because neither peptide is an FDA-approved drug, the marketplace around them is inconsistent, and this is a major reason the DIY route is risky.

The Purity and Contamination Problem

Products sold as “research chemicals” are not manufactured or tested to pharmaceutical standards. Independent testing of gray-market peptides has repeatedly found underdosed, overdosed, mislabeled, or contaminated material. Without third-party verification, a buyer cannot know what is actually in a vial — a serious concern for anything injected.

Why Physician Supervision Changes the Equation

In a supervised model, sourcing, screening, dosing, and monitoring are handled clinically rather than by the patient guessing. That is the entire value proposition of doing this through a medical provider instead of the internet: the peptide is only one part of a plan that includes evaluation, contraindication screening, technique, and follow-up.

Cost Context

Thin clinic and vendor pages often advertise Wolverine Stack packages in the low hundreds of dollars per cycle, but price says nothing about quality, appropriateness, or safety, and low cost can reflect low-quality raw material. Cost should never be the deciding factor for an injected, non-approved compound; clinical appropriateness should be. A consultation is the right place to discuss whether any protocol is worth pursuing for your situation.

Conclusion

The Wolverine Stack pairs BPC-157 and TB-500 on a sound-sounding premise: a local repair peptide plus a systemic one, working through complementary mechanisms to support soft-tissue recovery. The mechanistic story is genuinely interesting, and the individual peptides have real preclinical support — but the human evidence is thin, the combination has never been tested as a unit in a controlled trial, and neither compound is FDA-approved, with an unsettled 2026 compounding status. That combination of promise and uncertainty is exactly why this should never be a do-it-yourself project. If you are weighing a peptide protocol for an injury, the responsible path is a physician evaluation that weighs your history, your goals, and the real limits of the evidence. Schedule a peptide therapy consultation with Beverly Hills Rejuvenation Center to start that conversation.

Frequently Asked Questions About BPC-157 and TB-500 Dosing

What is the standard Wolverine Stack dosage?

Commonly referenced physician-directed protocols use BPC-157 at about 250–500 mcg per day subcutaneously, plus TB-500 at about 2–2.5 mg twice weekly during a 4–6 week loading phase, then 2–2.5 mg once weekly for maintenance. These figures come from animal data and clinical practice, not human efficacy trials, and any real dose must be set by a prescribing physician.

Do you inject BPC-157 and TB-500 together in the same syringe?

Usually no. The two are dosed on different schedules — BPC-157 daily, TB-500 once or twice weekly — so most days there is nothing to combine. On overlapping days some clinicians allow both in one syringe, but the safer default is separate injections, which keeps dosing precise and lets BPC-157 be placed near an injury while TB-500 goes in the abdomen. There is no rigorous compatibility study, so follow your provider’s direction.

How long should a Wolverine Stack cycle last?

Most combined cycles are described as 4–8 weeks, with some longer 8–12 week protocols for stubborn injuries. TB-500 typically loads for the first 4–6 weeks and then steps down to maintenance, while BPC-157 runs daily throughout. An off period of at least 4 weeks before any repeat cycle is common.

Why are BPC-157 and TB-500 stacked together?

The rationale is complementary mechanisms: BPC-157 is thought to work locally — angiogenesis and repair near the injury, plus gut protection — while TB-500 works systemically through actin regulation to support cell migration and blood-vessel formation body-wide. The idea is that one builds the local repair environment while the other supplies the cellular machinery. This synergy is a hypothesis extrapolated from separate studies, not a proven clinical result.

What’s the difference between BPC-157 and TB-500?

BPC-157 is a local, daily peptide often injected near an injury and uniquely associated with gastrointestinal protection. TB-500, related to thymosin beta-4, is a systemic peptide dosed a couple of times a week that acts body-wide through actin sequestration. They are stacked because they differ in scope rather than duplicating each other.

Where do you inject each peptide?

BPC-157 is often injected subcutaneously in the region nearest the targeted injury (or the abdomen for general or gut use). TB-500 is injected subcutaneously anywhere convenient — commonly the abdomen — because it distributes systemically and its site is not thought to matter. Sites should be rotated and never used over inflamed or broken skin.

What are the side effects of the Wolverine Stack?

Reported effects are mostly mild: injection-site redness, pain, swelling or lumps, fatigue (especially during TB-500 loading), occasional nausea, headache, or flushing. Because there are no long-term controlled human safety studies, the full profile is unknown, and the theoretical angiogenesis-related cancer concern makes active or recent malignancy a contraindication.

Are BPC-157 and TB-500 FDA-approved in 2026?

No. As of July 24, 2026 neither is FDA-approved. Both were removed from the 503A Category 2 list in April 2026 and reviewed by the FDA’s Pharmacy Compounding Advisory Committee on July 23–24, 2026, where the FDA took an unfavorable stance (for TB-500, proposing it not be added to the Bulks List, citing a lack of human effectiveness data). Their compounding status is unsettled and changing — verify the current position before relying on it.

How do you reconstitute the peptides for the stack?

Both come as a lyophilized powder reconstituted with bacteriostatic water. The water is injected slowly down the vial wall, the vial is gently swirled (never shaken) until clear, then labeled and refrigerated at 2–8°C for use within about 3–4 weeks. Concentration is chosen so the dose lands on a clean number of syringe units. In practice this is done by a pharmacist or clinician, not the patient.

Can athletes use the Wolverine Stack?

No, not if they are subject to drug testing. Both BPC-157 and TB-500 are on the WADA Prohibited List at all times, so using this stack would put a competitive or tested athlete at risk of a doping violation regardless of intent.

Related Resources From BHRC

• BPC-157 Dosage Guide: Complete Protocol for Safe Administration
• TB-500 Dosage Guide: Complete Protocol for Safe Administration
• CJC-1295 / Ipamorelin Peptide Therapy
• MOTS-c Peptide Therapy
• AOD-9604 Peptide Therapy
• Schedule a Peptide Therapy Consultation

About the Author & Medical Reviewer

Sam Brooks is a health and wellness content writer for Beverly Hills Rejuvenation Center who focuses on translating peptide and regenerative-medicine research into clear, accurate patient education.

About the medical review: This guide was reviewed by the clinical team at Beverly Hills Rejuvenation Center — board-certified physicians and licensed medical providers who oversee BHRC’s medical protocols and review its clinical education for accuracy, safety, and compliance. Reviewed July 24, 2026. This content is educational and does not replace an individual medical evaluation; peptide therapy at BHRC is physician-supervised.

References

1. Chang C-H, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID: 21030672.
2. Krivic A, et al. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. PMID: 18594781.
3. Chang C-H, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. PMC6271067.
4. Malinda KM, et al. Thymosin beta4 accelerates wound healing / the actin binding site on thymosin beta4 promotes angiogenesis. Ann N Y Acad Sci. 2003. PMID: 14500546.
5. Goldstein AL, Kleinman HK, et al. Thymosin β4: a multifunctional regenerative peptide in tissue repair (dimeric thymosin beta 4 accelerates wound healing). PMC3792846.
6. Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement of healing. PMID: 17495250.
7. Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers. ClinicalTrials.gov NCT00832091.
8. Study of Thymosin Beta 4 in Patients With Pressure Ulcers. ClinicalTrials.gov NCT00382174.
9. U.S. FDA. Section 503A Category 2 bulk drug substances list update (BPC-157 and TB-500 removal), April 2026; Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026. [INTERNAL-LINK TODO: confirm and add the final FDA.gov docket/announcement URL before publish.]

Final reminder: This article is educational and does not constitute medical advice, a prescription, or self-administration instructions. BPC-157 and TB-500 are not FDA-approved. Do not source or use either peptide outside of care directed by a licensed physician who has evaluated you.